GlassScriptPhysician profile
Alvaro Lacayo
NPI 1275693335
$7,076.61
in general payments reported to CMS, 2019-2025
22 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $83.87 · 2021: $719 · 2022: $1,530 · 2023: $1,922 · 2024: $1,564 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,619 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,619.35 |
| Education | $124.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,288.14 | 2020-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $805.16 | 2020-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $774.77 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $725.73 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $615.58 | 2022-2025 | Uzedy, Austedo |
| Abbvie INC. | $569.25 | 2022-2024 | |
| Ironshore Pharmaceuticals INC. | $419.71 | 2022-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $312.99 | 2022-2025 | Caplyta |
| Corium, LLC | $233.79 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $198.65 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $197.25 | 2021-2025 | Rexulti |
| Tris Pharma INC | $178.86 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Alkermes, INC. | $132.23 | 2021-2024 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $129.04 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $128.77 | 2022-2025 | Ingrezza, Ongentys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $115.52 | 2023-2025 | Auvelity |
| Biogen, INC. | $77.17 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $59.82 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $34.20 | 2022-2023 | Quviviq |
| Noven Therapeutics, LLC | $30.62 | 2024 | Xelstrym, Secuado |
| Adlon Therapeutics L.P. | $28.96 | 2021 | |
| Vertical Pharmaceuticals, LLC | $20.40 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvaro Lacayo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.